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Abstract
Background: Protease inhibitor monotherapy is associated with more frequent episodes of viral rebounds above
50 copies/mL than triple therapy. Objective: To evaluate if, compared to triple-drug therapy, protease inhibitor
monotherapy is associated with increased levels of inflammatory/procoagulant markers and more frequent plasma
residual viremia detection.
Methods: In this cross-sectional study, we included patients treated for≥ 1 year with darunavir/ritonavir or lopinavir/
ritonavir as monotherapy (n = 72) or with two nucleos(t)ides (n = 74). All samples were tested for CRP, IL-6, fibrinogen
and D-dimer. Residual viremia was determined using an ultrasensitive qualitative nested-PCR of the HIV pol gene with
a limit of detection of 1 copy of HIV-RNA.
Results: We found no differences in levels of inflammatory/procoagulant markers or in the proportion of patients with
plasma residual viremia detection by treatment group.
Conclusion: The long-term treatment with protease inhibitor monotherapy in the setting of routine clinical practice is
not associated with a higher prevalence of plasma residual viremia or more elevated inflammatory/procoagulant
markers levels than triple drug therapy.
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Background
In clinical trials, protease inhibitor (PI) monotherapy
(MT) has been effective in maintaining long-term viral
suppression in the majority of patients [1]. However,
MT is associated with more frequent episodes of viral
rebounds above 50 copies/mL than triple therapy (TT).
It has been suggested that episodes of low level viremia
might lead to higher levels of inflammation and pro-
coagulant markers such as interleukin-6 (IL-6), C-
reactive protein (CRP) and D-dimer.
In the MONET clinical trial [2], virologically suppressed
patients were randomized to darunavir/ritonavir as MT or
as TT. In a subset of patients enrolled in MONET no
differences were found in IL-6 and CRP levels between
the MT and TT arms in stored samples at week 144 [3].
In MONET, residual plasma viremia (RV) below 50 cop-
ies/mL was not directly measured so it remains un-
known if higher levels of inflammatory/procoagulant
markers are correlated with the level of RV. In the
present study we sought to investigate the relationship
between PI MT, levels of inflammatory/procoagulant
markers and RV.
Methods
The present study is a subanalysis of a parent study
comparing neurocognitive impairment in patients
treated with protease inhibitor monotherapy or triple
drug antiretroviral therapy. Details of this cohort and
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the recruitment flow-chart have been previously pub-
lished [4]. We included patients who were currently re-
ceiving for ≥ 1 year lopinavir or darunavir as MT or as
TT and had suppressed plasma viral load (<50 copies/
ml) for at least one year. 179 patients on MT were se-
lected, 41 patients rejected inclusion and 40 patients
were screening failure. In TT group, 238 patients were
selected. 49 patients rejected inclusion and 91 patients
were screening failure. So, 98 patients were recruited in
each group. After that, two patients on MT and three
patients on TT were excluded due to HIV-1 RNA above
50 copies/ml at the initial study visit. Finally, we in-
cluded 96 in the MT group and 95 patients in the TT
group in the parent study. In the present study, we had
available stored samples from 72 patients on MT and
74 patients on TT.
All samples were tested for CRP, IL-6, fibrinogen and
D-dimer. Routine determination of viral load was done
with Nuclisens EasyQ HIV-1 v2.0 (bioMeriéux, Marcy-
l’Étoile, France). This technique quantifies the viral
load above 20 copies/ml. At the same time-point,
plasma RV was determined using an ultrasensitive
qualitative nested-PCR of the HIV pol gene with a
limit of detection of 1 copy of HIV-RNA. This method
is based on the PCR used for single genome sequen-
cing [5]. The local Ethics Committee for Clinical Re-
search (La Paz University Hospital, Madrid) approved
all the procedures. All participants provided written in-
formed consent.
Sample characteristics were described using absolute
and relative frequencies for categorical variables and me-
dian (IQR) for continuous variables. Chi-square test and
Student’s t or the nonparametric Mann–Whitney U-test
were used to compare baseline characteristics. We evalu-
ated predictive factors of increased IL-6, CRP levels
using a multivariate lineal regression model on log-
transformed data. Explored factors were: age, sex, AIDS,
CD4 (nadir/current), prior medical disease, hepatitis C
(defined by HCV serum PCR), duration of viral sup-
pression, detection of RV, blips (HIV RNA level > 50
copies/ml) in the last year, group of treatment, type of
PI, triglycerides, total cholesterol/LDL ratio, total chol-
esterol/HDL ratio, HOMA index and use of statins.
Variables with a p-value <0.1 in the univariate analysis,
were retained in the model. All analyses were per-
formed using the STATA statistical package (V.11.1,
Stata Corporation, College Station, Texas, USA). All
tests were 2-sided, p values <0.05 were considered
significant.
Results and discussion
Patients were predominantly male, with a median age of
46 years, and good immune status (Table 1). Compared
to the TT group, the MT group showed significantly
longer duration of suppressed HIV viremia (median 7.1
versus 4.7 years, p = 0.019). The median of time on PI
monotherapy was 2.6 years (IQR 1.9-3.9).
We found no differences in levels of inflammatory/
procoagulant markers between groups of treatment.
Specifically we have not found differences in IL-6
levels ≥3 pg/mL and CRP levels ≥ 5 mg which have
been associated with higher rates of progression to
AIDS or death and an increased cardiovascular risk
[6,7]. These results are comparable to those of the
MONET trial [3]. In the multivariate analysis, the vari-
ables significantly associated with increased IL-6 level
were male gender (p = 0.017), older age (p = 0.009) and
active hepatitis C (p = 0.043) and the variable signifi-
cantly associated to increased CRP levels was the
HOMA index (p = 0.030). Hepatitis C coinfection was
also associated with higher IL-6 level in the MONET
trial [3]. Overall, there was a significant weak correl-
ation between higher IL-6 levels and higher CRP levels
(correlation coefficient = 0.35, p < 0.001). The detection
of RV was similar in both groups of treatment (44.6%
in TT group vs. 38.9% in MT group, p = 0.484). The
percentage of patients with viral load 20–49 copies/ml
was higher in triple therapy group (p = 0.081). There
were no differences in inflammatory/procoagulant
markers or detection of RV between patients receiving
MT with Lopinavir/r or Darunavir/r.
We have found that the use of PI MT in routine clin-
ical practice, compared to TT, is not associated to higher
levels of inflammatory or procoagulant markers. Inter-
estingly, as in prior studies [3,8] hepatitis C coinfection
was significantly associated to higher IL-6 level.
In our study, plasma RV -detectable in nearly half of
patients- was not more frequent in patients receiving
MT. In the “Only Kaletra” pilot trial [9] the level of RV
did not increase after switching from TT to lopinavir/ri-
tonavir MT. In the MONET clinical trial the percentage
of patients with HIV RNA <5 copies/mL remained con-
stant over time without differences between MT and TT
[10]. In the MONOI trial, among patients with viral load
<50 copies/ml at week 48 there was no difference in the
proportions of patients with HIV RNA < 1 copy/mL at
week 48 [11]. Taken together these results do not sug-
gest that MT is associated with more frequent detection
of RV.
Our study did not show an association between de-
tection of RV and higher levels of inflammatory/pro-
coagulant markers. In the study by Chun et al. [12]
RV was detected in 63% of virologically suppressed
patients with no association with increased levels of
inflammatory/procoagulant markers. In the FRAM co-
hort, there was little association of low-level viremia
with levels of CRP, IL-6 and fibrinogen. Only in
patients with viral loads above 10,000 HIV-RNA
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copies/mL there was an association with increased IL-6
levels [13].
Our study has the intrinsic limitations of cross-
sectional analyses. We compared MT and TT in a se-
lected group of patients, who have maintained long-term
virological suppression and results cannot be extrapo-
lated to other types of patients. However this limitation
is inherent to the fact that MT is only indicated in ad-
herent patients with suppressed viral load [14]. The
time on viral suppression was significantly longer in
the MT group, which could have decreased the possi-
bility of detection of residual viremia in this group.
However, the duration of viral suppression and the
group the treatment were not significantly associated
with increased levels of IL-6 and CRP in the multivari-
ate analysis.
Conclusion
In summary, our study suggests that long-term treat-
ment with darunavir/ritonavir or lopinavir/ritonavir MT
in the setting of routine clinical practice is not associated
with a higher prevalence of plasma RV or more elevated
inflammatory/procoagulant markers levels than triple
drug therapy.
Table 1 Demographics characteristics, HIV disease status and laboratory results
Triple therapy (n = 74) Monotherapy (n = 72) p-value
Receiving darunavir/ritonavir. N (%) 19 (26) 27 (37.5) 0.124
Receiving abacavir. N (%) 12 (16.2) NA
Receiving tenofovir. N (%) 60 (81.0) NA
Receiving zidovudine. N (%) 2 (2.7) NA
Receiving lamivudine. N (%) 20 (27.0) NA
Receiving emtricitabine. N (%) 54 (72.9) NA
Male. N (%) 52 (70.3) 52 (72.2) 0.794
Age. Median (IQR) 44 (40–48) 47 (44–51) 0.002
Prior medical disease*. N (%) 27 (36.5) 36 (50) 0.099
Hepatitis C active. N (%) 18 (24.3) 14 (19.4) 0.932
AIDS. N (%) 47 (63.5) 44 (61.1) 0.764
CD4 nadir (cells/μL). Median (IQR) 141 (47–244) 172 (53–268) 0.376
Current CD4 (cells/μL). Median (IQR) 576 (417–805) 623 (457–834) 0.225
Years virologically suppressed.
Median (IQR) 4.7 (2.9–8.9) 7.1 (4.5–8.9) 0.019
Monotherapy NA 2.6 (1.9–3.9)
Patients with a single blip **. N (%) 8 (10.8) 4 (5.5) 0.249
Detectable HIV RNA (Ultrasensitive assay). N (%) 33 (44.6) 28 (38.9) 0.484
HIV RNA 20–49 copies/ml. N (%) 12 (16.2) 5 (6.9) 0.081
Triglycerides (mg/dL). Median (IQR) 149 (111–196) 189 (137–248) 0.007
LDL Cholesterol. Median (IQR) 125 (107–153) 132 (110–156) 0.161
Total Cholesterol/HDL ratio. Median (IQR) 3.8 (3.3–4.7) 4.6 (3.7–5.6) 0.003
Total Cholesterol/LDL ratio. Median (IQR) 1.6 (1.5–1.8) 1.6 (1.5–1.8) 0.668
Receiving statins. N (%) 17 (25.4) 16 (24) 0.484
HOMA index. Median (IQR) 1.7 (1.0–2.7) 2.1 (1.3–3.4) 0.105
CRP level(mg/L).Median (IQR) 0.9 (0–2.4) 1.3 (0–2.8) 0.478
CRP ≥5 mg/L. N (%) 5 (6.8) 10 (14.5) 0.139
IL-6 (pg/ml).
Median(IQR) 1.9 (1.2–3.4) 1.7 (1.3–3) 0.504
IL-6≥ 3 pg/ml. N (%) 17 (23) 18 (25) 0.774
Fibrinogen (mg/dl). Median (IQR) 386 (351–452) 398 (362–447) 0.372
D-dimer (ng/ml). Median (IQR) 131 (99–214) 137 (99–234) 0.769
Medical disease: hypertension, dyslipaemia, diabetes mellitus, ischemic heart disease, heart insufficiency, chronic renal failure, thyroid disorders and peripheral
arterial disease*. Blip: detection of RNA-HIV > 50 copies/ml in the last year**. NA: non applicable.
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